TRIN
Trinity Capital Inc. NASDAQ Listed Jan 29, 2021$17.02
Mkt Cap $1.2B
52w Low $13.76
90.1% of range
52w High $17.38
50d MA $15.27
200d MA $15.40
P/E (TTM)
8.5x
EV/EBITDA
10.7x
P/B
1.1x
Debt/Equity
1.2x
ROE
12.4%
P/FCF
-1.9x
RSI (14)
—
ATR (14)
—
Beta
0.62
50d MA
$15.27
200d MA
$15.40
Avg Volume
1.4M
Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in Lutherville-Timonium, Maryland, San Diego, California and Austin, Texas.
CIK (SEC)
Phone
480 374 5350
1 N. 1st Street · Phoenix, AZ 85004-2357 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | 0.51 | 0.52 | +2.0% | 15.40 | +0.1% | -1.3% | -2.7% | +0.8% | -0.1% | +1.4% | — |
| Nov 5, 2025 | BMO | 0.52 | 0.52 | +0.0% | 14.41 | +1.0% | +0.0% | +1.3% | +0.8% | +1.5% | -0.1% | — |
| Aug 6, 2025 | BMO | 0.52 | 0.53 | +1.9% | 15.33 | +0.5% | +1.0% | +2.2% | -0.4% | +0.8% | +1.6% | — |
| May 7, 2025 | BMO | 0.53 | 0.52 | -1.9% | 13.83 | +2.7% | +2.1% | +0.9% | +2.4% | +1.5% | -0.3% | — |
| Apr 29, 2025 | BMO | — | 0.72 | — | 14.70 | -0.7% | -1.2% | -2.1% | +0.7% | -1.3% | -0.3% | — |
| Oct 30, 2024 | BMO | 0.52 | 0.54 | +3.8% | 13.62 | -0.1% | +1.2% | -3.1% | -1.8% | +2.0% | +2.2% | — |
| Aug 7, 2024 | BMO | 0.52 | 0.51 | -1.9% | 14.43 | +0.7% | +0.4% | -0.4% | -0.7% | -1.1% | +0.3% | — |
| May 1, 2024 | BMO | 0.55 | 0.52 | -5.5% | 14.71 | +0.0% | -1.6% | +1.0% | +1.3% | +0.1% | +0.0% | — |
| Mar 6, 2024 | BMO | 0.55 | 0.54 | -1.8% | 14.89 | +0.8% | +1.3% | -1.5% | +0.3% | +0.3% | +0.4% | — |
| Nov 1, 2023 | BMO | 0.55 | 0.55 | +0.0% | 14.29 | +0.8% | +2.0% | +0.1% | -1.3% | -0.3% | +0.7% | — |
| Aug 2, 2023 | BMO | 0.53 | 0.61 | +15.1% | 15.00 | +0.7% | +1.9% | -7.7% | +0.4% | -0.2% | -0.6% | — |
| May 4, 2023 | BMO | 0.57 | 0.52 | -8.8% | 11.78 | +2.4% | +0.3% | +0.0% | -0.9% | -0.1% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14 | UBS | Maintains | Buy → Buy | — | $14.83 | $14.80 | -0.2% | +1.1% | +0.9% | -3.0% | +0.7% | -0.4% |
| Aug 12 | Wells Fargo | Maintains | Underweight → Underweight | — | $15.75 | $15.80 | +0.3% | +0.8% | +1.6% | -0.1% | -1.0% | -0.2% |
| Aug 7 | B. Riley Securities | Maintains | Buy → Buy | — | $15.33 | $15.40 | +0.5% | +1.0% | +2.2% | -0.4% | +0.8% | +1.6% |
| Jul 16 | UBS | Maintains | Buy → Buy | — | $14.52 | $14.60 | +0.6% | +1.9% | +1.1% | +0.0% | -0.9% | +0.7% |
| May 8 | Keefe, Bruyette & Woods | Maintains | Market Perform → Market Perform | — | $13.83 | $14.20 | +2.7% | +2.1% | +0.9% | +2.4% | +1.5% | -0.3% |
| Apr 28 | Wells Fargo | Maintains | Underweight → Underweight | — | $14.86 | $14.83 | -0.2% | -0.1% | -0.9% | -1.2% | -2.1% | +0.7% |
| Apr 17 | UBS | Maintains | Buy → Buy | — | $14.13 | $14.15 | +0.1% | +1.3% | -2.2% | +2.1% | +1.5% | +1.3% |
| Feb 28 | Wells Fargo | Maintains | Underweight → Underweight | — | $16.22 | $16.28 | +0.4% | +2.1% | -0.7% | -1.7% | -0.9% | -1.7% |
| Feb 27 | Keefe, Bruyette & Woods | Maintains | Market Perform → Market Perform | — | $16.54 | $16.65 | +0.7% | -1.9% | +2.1% | -0.7% | -1.7% | -0.9% |
| Dec 2 | Wells Fargo | Downgrade | Equal Weight → Underweight | — | $14.67 | $14.47 | -1.4% | -1.6% | -0.7% | +0.4% | -0.9% | +0.2% |
| Oct 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.88 | $13.83 | -0.4% | -2.1% | +0.2% | +1.2% | -3.1% | -1.8% |
| May 2 | B. Riley Securities | Maintains | Buy → Buy | — | $14.71 | $14.71 | +0.0% | -1.6% | +1.0% | +1.3% | +0.1% | +0.0% |
| Mar 18 | UBS | Maintains | Buy → Buy | — | $14.80 | $14.87 | +0.5% | -0.3% | +0.0% | +0.1% | +1.1% | +0.0% |
| Mar 7 | B. Riley Securities | Maintains | Buy → Buy | — | $14.89 | $15.01 | +0.8% | +1.3% | -1.5% | +0.3% | +0.3% | +0.4% |
| Aug 22 | Compass Point | Upgrade | Neutral → Buy | — | $14.35 | $14.58 | +1.6% | -1.3% | +2.5% | -1.8% | +0.7% | +0.8% |
| Aug 17 | UBS | Maintains | Buy → Buy | — | $13.98 | $13.98 | +0.0% | +2.6% | -0.3% | +0.3% | -1.3% | +2.5% |
| Aug 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.00 | $15.10 | +0.7% | +1.9% | -7.7% | +0.4% | -0.2% | -0.6% |
| Aug 2 | B. Riley Securities | Maintains | Buy → Buy | — | $14.58 | $14.73 | +1.0% | +2.9% | +1.9% | -7.7% | +0.4% | -0.2% |
| May 8 | B. Riley Securities | Maintains | Buy → Buy | — | $11.82 | $12.03 | +1.8% | +0.0% | -0.9% | -0.1% | -0.9% | -1.7% |
| May 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.82 | $12.03 | +1.8% | +0.0% | -0.9% | -0.1% | -0.9% | -1.7% |
| Apr 18 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.79 | $12.73 | -0.5% | -2.8% | -0.5% | -1.4% | -0.7% | -0.9% |
| Mar 13 | Keefe, Bruyette & Woods | Downgrade | Market Perform → Underperform | — | $12.40 | $12.15 | -2.0% | -6.5% | +8.1% | +2.6% | +2.6% | -1.2% |
| Mar 6 | B. Riley Securities | Maintains | Buy → Buy | — | $14.26 | $14.50 | +1.7% | -1.0% | +0.0% | -0.2% | -4.0% | -8.4% |
| Mar 3 | Keefe, Bruyette & Woods | Maintains | Market Perform → Market Perform | — | $13.39 | $14.18 | +5.9% | +6.5% | -1.0% | +0.0% | -0.2% | -4.0% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.00 | $11.00 | +0.0% | +0.5% | -4.1% | +0.0% | +3.3% | +1.6% |
| Nov 4 | Keefe, Bruyette & Woods | Downgrade | Outperform → Market Perform | — | $11.31 | $11.10 | -1.9% | -2.7% | +0.5% | -4.1% | +0.0% | +3.3% |
| Oct 28 | Compass Point | Downgrade | Buy → Neutral | — | $12.33 | $12.28 | -0.4% | -2.4% | -0.9% | +2.0% | -2.8% | -4.3% |
| Oct 27 | Compass Point | Downgrade | Buy → Neutral | — | $13.82 | $13.75 | -0.5% | -10.8% | -2.4% | -0.9% | +2.0% | -2.8% |
| Oct 24 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.30 | $13.35 | +0.4% | +0.2% | +2.9% | +0.9% | -10.8% | -2.4% |
| Jul 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $14.89 | $14.38 | -3.4% | -2.3% | -2.1% | +1.6% | +0.7% | +1.0% |
| May 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.57 | $16.46 | +5.7% | +0.6% | -1.0% | -1.8% | +0.5% | +1.8% |
| Oct 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.97 | $16.00 | +0.2% | +1.3% | -1.4% | +0.8% | +1.4% | -0.9% |
| Aug 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.25 | $15.25 | +0.0% | -0.1% | -1.1% | +0.9% | -1.3% | +1.7% |
| May 7 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $15.00 | $15.03 | +0.2% | -0.4% | +0.1% | -2.1% | -1.1% | -0.6% |
| May 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.59 | $14.60 | +0.1% | +0.5% | +1.2% | +1.1% | -0.4% | +0.1% |
No insider trades available.
8-K
Crescent Capital BDC, Inc. -- 8-K Filing
May 8
8-K · 2.02
!! High
Trinity Capital Inc. -- 8-K 2.02: Earnings Results
Trinity Capital reported quarterly earnings results; investors should review the attached press release for detailed financial performance metrics and management guidance affecting the stock's valuation.
May 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Trinity Capital's strong $395M commitment growth and $306M funding in Q1 2026 signals robust business momentum and portfolio expansion, supporting revenue visibility and justifying continued investor confidence in the alternative asset manager's growth trajectory.
Apr 10
8-K
Unknown — 8-K Filing
Candel Therapeutics secured $130 million in debt financing, extending its cash runway to advance cancer immunotherapy development, but increasing financial obligations that could dilute shareholders if clinical trials fail.
Mar 12
8-K · 7.01
! Medium
Trinity Capital Inc. 7.875% Notes due 2029 -- 8-K 7.01: Regulation FD Disclosure
Trinity Capital disclosed its Q4 2025 earnings presentation ahead of its February 25 conference call, providing investors transparency into fourth-quarter and full-year results through regulated disclosure channels.
Feb 25
8-K
Trinity Capital Inc. 7.875% Notes due 2029 -- 8-K Filing
Trinity Capital Inc. reported preliminary fourth quarter and full-year 2025 financial results, providing investors with early earnings guidance ahead of full disclosure, impacting expectations for the company's debt-financed business performance.
Feb 3
Data updated apr 27, 2026 5:35am
· Source: massive.com